Version history

{
  "session_id": "sess_SDA-2026-04-08-gap-pubmed-20260406-062202-5c32c50a_task_9aae8fc5",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "scidex.core.llm.complete",
  "action": "propose",
  "content": "# Mechanistic Hypotheses: TDP-43 Contribution to Cognitive Impairment Severity in AD\n\n## Hypothesis 1: Synaptic RNA Metabolism Dysregulation\n\n**Title:** TDP-43-mediated disruption of synaptic mRNA trafficking and local translation leads to synaptic failure\n\n**Mechanism:** Cytoplasmic TDP-43 accumulation in AD neurons disrupts its normal nuclear function while sequestering target mRNAs at synapses. This impairs local protein synthesis critical for synaptic plasticity, particularly in dendritic compartments. TDP-43 pathologically phosphorylated at S409/410 (as seen in AD) exhibits altered RNA binding affinity, mislocalizing synaptic transcripts including those encoding glutamate receptors (GRIA1, GRIA2) and scaffold proteins (PSD-95/DLG4).\n\n**Target Gene/Protein/Pathway:** \n- Primary: TARDBP (TDP-43 protein)\n- Downstream: Synaptic mRNA regulons (e.g., CaMKIIα, Arc, GluA1)\n- Pathway: mRNA export/splicing (TDP-43 nuclear export vs. cytoplasmic aggregation)\n\n**Supporting Evidence:**\n- TDP-43 pathology correlates with synaptic loss independent of amyloid burden (PMID: 34930382 - source paper)\n- TDP-43 knockout mice show synaptic dysfunction and behavioral deficits (PMID: 23993254)\n- AD brains with TDP-43 show accelerated cognitive decline and increased synaptic pathology markers\n\n**Predicted Experiment:** \nPerform snRNA-seq from postmortem AD prefrontal cortex comparing Aβ+/TDP-43+ vs Aβ+/TDP-43- cases. Validate synaptic transcriptome changes via spatial transcriptomics on adjacent sections. Test whether AAV-mediated expression of nuclear-restored TDP-43 (S403/404 non-phosphorylatable mutant) in 5xFAD/TDP-43 P301L mice restores synaptic protein expression and reverses cognitive deficits on Morris water maze.\n\n**Confidence:** 0.72\n\n---\n\n## Hypothesis 2: Mitochondrial Proteostasis Hijacking\n\n**Title:** Pathological TDP-43 sequesters mitochondrial RNA metabolism factors, precipitating bioenergetic failure\n\n**Mechanism:** TDP-43 forms pathological inclusions that colocalize with mitochondria in affected neurons, co-aggregating key mitochondrial genome maintenance and electron transport chain (ETC) mRNAs. This disrupts mitochondrial dynamics, reduces ATP production, and increases reactive oxygen species (ROS). The resulting bioenergetic failure disproportionately affects high-energy-demand processes like neurotransmission and memory consolidation.\n\n**Target Gene/Protein/Pathway:**\n- Primary: TDP-43 aggregation (phosphorylated, C-terminal fragments)\n- Secondary: Mitochondrial translation factors (MRPS22, MRPL47), ETC complex I-IV subunits\n- Pathway: Mitochondrial unfolded protein response (mtUPR), TOMM40 import\n\n**Supporting Evidence:**\n- Mitochondrial dysfunction is well-documented in AD (PMID: 30509181)\n- TDP-43 directly interacts with mitochondrial transcripts in ALS models (PMID: 29891979)\n- Proteomic studies show mitochondrial dysfunction co-segregates with TDP-43 in AD\n\n**Predicted Experiment:**\nUse mitochondrial fractionation + proteomics in postmortem AD brain tissue (Aβ+/TDP-43+ vs. controls) to identify TDP-43-bound mitochondrial proteins. Test in iPSC-derived neurons from AD patients with TDP-43 pathology whether mitochondrial-targeted antioxidants (MitoQ) rescue TDP-43-associated synaptic deficits. Measure oxygen consumption rate (OCR) in 3D neural cultures.\n\n**Confidence:** 0.58\n\n---\n\n## Hypothesis 3: Glial Neuroinflammatory Amplification\n\n**Title:** TDP-43 pathology in astrocytes/microglia triggers non-cell-autonomous neuroinflammation degrading cognitive circuits\n\n**Mechanism:** TDP-43 pathology is not restricted to neurons in AD—it also accumulates in astrocytes and microglia. Astrocyte TDP-43 pathology disrupts their homeostatic transcriptional program (Gfap, SLC1A2/EAAT2 downregulation), while microglial TDP-43 burden drives a disease-associated microglia (DAM) or neurodegenerative (MGnD) signature. The resulting chronic neuroinflammation impairs synaptic pruning, reduces glutamate clearance, and activates excitotoxic pathways.\n\n**Target Gene/Protein/Pathway:**\n- Primary: TDP-43 in non-neuronal cells (astrocytes, microglia)\n- Secondary: NF-κB signaling, NLRP3 inflammasome, complement cascade\n- Pathway: Neuroinflammation, synaptic pruning dysregulation\n\n**Supporting Evidence:**\n- TDP-43 inclusions observed in astrocytes in AD (PMID: 31006700)\n- MGnD microglia signature associated with worse outcomes in neurodegenerative disease\n- Neuroinflammation correlates with cognitive impairment severity in AD\n\n**Predicted Experiment:**\nPerform single-nucleus RNA-seq from AD cases with/without TDP-43 pathology, focusing on glia. Use cell-type-specific AAV-Cre in TDP-43flox/flox mice crossed to GFAP-Cre or CX3CR1-Cre lines to selectively knock down TDP-43 in astrocytes or microglia. Measure microglial synaptic pruning (complement C1q, C3), astrocyte glutamate uptake, and cognitive performance on 5-month functional batteries.\n\n**Confidence:** 0.65\n\n---\n\n## Hypothesis 4: Tau Cross-Seeding and Interaction\n\n**Title:** TDP-43 acts as a co-pathogen accelerating tau aggregation and spreading\n\n**Mechanism:** TDP-43 and tau co-aggregate in a subset of AD cases, suggesting cross-talk. TDP-43 may function as an RNA scaffold that nucleates pathological tau fibrils, or may phosphorylate tau via dysregulated kinases (GSK3β, CDK5). Conversely, tau pathology may promote cytoplasmic TDP-43 mislocalization. This bidirectional interaction creates a feed-forward loop accelerating both pathologies, explaining the synergistic cognitive decline.\n\n**Target Gene/Protein/Pathway:**\n- Primary: TDP-43 × Tau (MAPT) interaction\n- Secondary: CDK5, GSK3β kinases; PP2A phosphatase\n- Pathway: Protein aggregation propagation, phosphorylation cascades\n\n**Supporting Evidence:**\n- TDP-43 and tau inclusions colocalize in ~25% of AD cases (PMID: 29249366)\n- Tau pathology severity correlates with TDP-43 burden in limbic regions\n- TDP-43 phosphorylation at S409/410 is associated with late-stage AD\n\n**Predicted Experiment:**\nUse cross-seeding assays: incubate recombinant tau fibrils with TDP-43 liquid-liquid phase separated droplets, assess whether TDP-43 promotes faster/more extensive tau fibrilization via ThT fluorescence and EM. In P301S tau mice (rapid tauopathy model), cross with TDP-43 A315T knock-in or viral overexpression of phospho-mimetic TDP-43 (S409/410D), assess whether TDP-43 accelerates tau spreading, behavioral decline, and synapse loss.\n\n**Confidence:** 0.70\n\n---\n\n## Hypothesis 5: Nucleocytoplasmic Transport Disruption\n\n**Title:** TDP-43 aggregation disrupts nucleocytoplasmic shuttling, trapping transcription factors and enhancing neurodegeneration\n\n**Mechanism:** Pathological TDP-43 aggregates in the cytoplasm impair the nuclear pore complex (NPC) and import/export machinery, blocking proper nucleocytoplasmic transport. This traps transcription factors (REST, NRF2) in the cytoplasm, preventing their neuroprotective transcriptional programs. Additionally, ribosomal biogenesis is disrupted in the nucleus, impairing global protein synthesis and leading to synaptic proteostasis failure.\n\n**Target Gene/Protein/Pathway:**\n- Primary: TDP-43 aggregation → NPC dysfunction\n- Secondary: Karyopherins (KPNA2, KPNB1), NUP107, NUP205\n- Pathway: Nucleocytoplasmic transport, transcriptional regulation, ribosomal biogenesis\n\n**Supporting Evidence:**\n- TDP-43 pathology in ALS/FTLD disrupts nucleocytoplasmic transport (PMID: 29130313, 29686386)\n- NUPs mislocalize in TDP-43 models\n- REST deficiency correlates with cognitive decline in AD (PMID: 24302769)\n\n**Predicted Experiment:**\nUse iPSC-derived neurons from AD patients with TDP-43 pathology and isogenic controls to measure nuclear import kinetics via GFP-tagged reporter assays (STAT2 nuclear import). Perform proximity ligation assay (PLA) for TDP-43-NUP complexes. Test whether overexpression of NUP107 or karyopherin β1 rescues transcriptional programs (RNA-seq) and restores synaptic function. Validate in postmortem tissue via immunohistochemistry.\n\n**Confidence:** 0.62\n\n---\n\n## Summary Table\n\n| Hypothesis",
  "tokens_used": "2014",
  "persona_id": "persona-theorist"
}